5 Stocks to Watch: Week of 10/20/2025

Happy Weekend! Let’s get right to the stocks to watch for the coming week:

• BeOne Medicines (ONC) demonstrates solid growth
• Past Stock of the Week pick pick Jones Lang Lasalle (JLL) is back on our radar
• MasTec (MTZ) is killing it right now — here’s why Strong Buy alerts are flashing 
• Array Technologies (ARRY) is a dazzling solar company with 70%+ potential upside 
• Ibex (IBEX) is our latest Stock of the Week — find out why

Let's get to it:

A note from our sponsors...

1- Ibex (NASDAQ: IBEX)

Ibex is an up-and-coming customer experience outsourcer that serves a variety of industries. It’s also our Stock of the Week. IBEX had a strong rally after a recent earnings beat, but has since gone down to a bargain price — and our Editor-in-Chief believes the stock could see prices increase by 35% by the end of the year if the company manages to extend its already impressive earnings beat streak.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $36.84 — get current quote > 

Max 1-year forecast: $39.00 

Why we’re watching:

• IBEX is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained why he added it to his exclusive 20-stock strong Zen Investor portfolio in a Monday article.
• At the moment, large caps are, generally speaking, quite overvalued — in contrast, small-cap stocks like Ibex tend to have more upside potential
• The stock has a Zen Rating of A, and is actually ranked 3rd overall out of the roughly 4,600 equities that we track.
• After a recent earnings beat, IBEX shares rocketed up to $43 — having since receded back down to the mid $30’s, now is an opportune time to Buy the Dip.
• If the beat and raise cycle continues, our Editor-in-Chief believes that IBEX could reach prices as high as $50 by the end of the year, and possibly double its current price by the end of 2026.
• IBEX has some pretty compelling scores in terms of its Component Grade ratings. The stock ranks in the top 25% for Growth and the top 22% for Safety.
• In addition, Ibex shares rank in the top 10% with regard to the Momentum Component Grade rating.
• IBEX is also the top-rated stock in the Information Technology Service industry, which has an Industry Rating of B.
• Despite being a relatively low-profile stock, IBEX has attracted attention from the Smart Money crowd, as it ranks in the top 7% when it comes to Sentiment.
• Ibex stock is currently trading at an attractive P/E ratio of 14.68x and an even more attractive PEG ratio of just 0.56x — so it’s little wonder that it ranks in the 97th percentile according to Value.
• Last, but certainly not least is the company’s impressive balance sheet — which has placed IBEX in the top 1% of stocks in terms of Financials. (See all 7 Zen Component Grades here >)

2- BeOne Medicines (NASDAQ: ONC) 

BeOne Medicines is an oncology-focused biotech business that has demonstrated solid EPS growth thus far in 2025. ONC has rallied by 73.97% since the start of the year, and one of Wall Street’s finest analysts believes there’s still double-digit upside in the cards — to further sweeten the pot, the stock has dipped by almost 7% in the past week, so it’s currently trading at a discount.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $318.02 — get current quote > 

Max 1-year forecast: $385.00 

Why we’re watching:

• BeOne Medicines is covered by 7 Wall Street analysts — their coverage is split between 5 Strong Buy ratings and 2 Buy ratings. See the ratings 
• The average 12-month price forecast for ONC shares, currently pegged at $353.43, implies a healthy 10.41% upside.
• JP Morgan researcher Jessica Fye (a top 4% rated analyst) recently maintained a Strong Buy rating on the stock and increased her price target from $345 to a Street-high $385.
• Fye contextualized their price target hike on BeOne Medicines by arguing that its "broad" oncology pipeline supports "durable" growth.
• Looking ahead, the analyst detailed that "two value-inflecting pivotal data readouts for BeOne Medicines as visible, data for its BTK inhibitor in first-line mantle cell lymphoma in 2H 2025, and data in first-line gastroesophageal cancer for its PD1 inhibitor, anti-HER2 combination in Q4."
• Our quant rating system, Zen Ratings, evaluates stocks on the basis of 115 proprietary factors. The equities that rank in the top 5% are given a Zen Rating of A — and have provided an average annual return of 32.52% since the early 2000s. At present, ONC ranks in the top 4% of the stocks that we track.
• Each Zen Rating is a composite score made up from 7 Component Grade ratings. So, for instance, ONC ranks in the top 18% in terms of Momentum, and the top 16% when it comes to Value.
• BeOne Medicines shares also rank in the top 6% with regard to Artificial Intelligence. This means that a neural network trained on more than two decades of market data has identified the stock as a likely outperformer.
• Lastly, we have the star of the show — Growth. Here, ONC ranks in the 99th percentile of the stocks that we track. (See all 7 Zen Component Grades here >)

3- Jones Lang Lasalle (NYSE: JLL)

Real estate markets tend to ebb and flow — but Jones Lang Lasalle has been in business since 1997, and has managed to both weather crises and thrive when conditions are favorable. Our Stock of the Week has been named one of the most admired companies in the world by Fortune magazine. Five consecutive earnings beats have proven that this real estate business has kept up with the times — and we have reason to believe it will continue to outperform.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $296.72 — get current quote > 

Max 1-year forecast: $378.00 

Why we’re watching:

• JLL shares have 3 Strong Buy ratings, 1 Buy rating, and 1 Hold rating. See the ratings  
• The average 12-month price forecast for Jones Lang Lasalle stock is currently pegged at $339, and implies a hefty 19.69% upside.
• UBS equity researcher Alex Kramm (a top 12% rated analyst) maintained a Strong Buy rating on the stock ahead of the company’s Q3 2025 earnings report, due November 5. Kramm also increased his price target from $340 to $370.
• In a U.S. Real Estate Brokers sector quarterly preview note, Kramm told readers to expect results showing that recovery is continuing at a moderating pace.
• Jones Lang Lasalle shares rank in the top 9% of the equities that we track, giving them a Zen Rating of B, which has historically corresponded to an average annual return of 19.88%.
• JLL ranks in the top 25% in terms of Value, as the stock is currently trading at a very attractive price to earnings (P/E) ratio of 23.86x and a price to earnings growth (PEG) ratio of 0.9xx.
• Our Sentiment Component Grade rating takes into account factors such as earnings surprises, short interest, earnings revisions, and insider buying or selling. In this category, Jones Lang Lasalle ranks in the 77th percentile.
• Safety is another high point here — when it comes to this Component Grade rating, the stock ranks in the top 22%.
• However, the company’s balance sheet is its strongest suit — with regard to Financials, JLL ranks in the 89th percentile of the equities that we track. (See all 7 Zen Component Grades here >)

A note from our sponsors...

4- Array Technologies (NASDAQ: ARRY) 

Based in New Mexico, Array Technologies is a leading provider of solar tracking systems that help maximize the efficiency of utility-scale solar projects. The business enjoys a strong balance sheet, even stronger growth prospects, and some of Wall Street’s finest are projecting significant upside to come.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $8.95 — get current quote > 

Max 1-year forecast: $15.00

Why we’re watching:

• Array Technologies shares have 7 Strong Buy ratings, 1 Buy rating, 5 Hold ratings, and 1 Sell rating. See the ratings  
• Guggenheim equity researcher Joseph Osha (a top 3% rated analyst) maintained a Strong Buy rating on the stock ahead of the company’s Q3 2025 earnings report, due November 5, and increased his price target from $12 to a Street-high $15.
• In an early preview note, Osha attributed their price target hike to takeaways from conversations with management and data from industry checks.
• ARRY ranks in the top 3% of the equities that we track, giving it a Zen Rating of A, which has historically corresponded to an average annual return of 32.52%.
• In terms of its Artificial Intelligence Component Grade rating, Array Technologies ranks in the top 20% of stocks — meaning that a neural network trained on more than two decades of market data has identified it as a likely outperformer.
• When it comes to its Financials Component Grade rating, ARRY ranks in the 82nd percentile of stocks.
• However, Growth is the stock’s strongest suit — here, Array Technologies ranks in the top 1%. (See all 7 Zen Component Grades here >)

5- Taiwan Semiconductor Manufacturing (NYSE: TSM) 

Occasionally referred to as the most important company in the world, TSM is a key semiconductor player that enjoys a nigh-impenetrable moat when it comes to chip manufacturing. The stock has been on a tear since the start of the year — and two highly-rated Wall Street analysts are anticipating that Taiwan Semiconductor Manufacturing’s soon-to-be-released quarterly report will provide a catalyst for further upside.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $297.78 — get current quote > 

Max 1-year forecast: $400.00 

Why we’re watching:

• At present, 3 Wall Street analysts track TSM and issue ratings for it — their coverage is split between 2 Strong Buy ratings and 1 Buy rating. See the ratings 
• The average 12-month price forecast for Taiwan Semiconductor Manufacturing currently sits at $333.33, and implies a hefty 18.77% upside.
• Susquehanna researcher Mehdi Hosseini (a top 5% rated analyst) maintained a Strong Buy rating on TSM ahead of the company’s Q3 2025 earnings, due October 16, and increased his price target from $300 to a Street-high $400.
• In an upbeat preview note, Hosseini told readers to expect beat and raise results.
• Looking ahead, with Q4 2025 and Q1 2026 already tracking ahead of consensus and seasonal trends, TSMC will enjoy another exceptionally strong year, the analyst said.
• Simon Coles of Barclays (a top 26% rated analyst) also maintained a Strong Buy rating on the stock, and increased his price target from $325 to $330.
• In a preview note, Coles backgrounded that recent announcements have redirected European semi-cap stocks back towards highs last seen in Q2 2024.
• Barclays is now more positive on wafer fab equipment names in 2026 and 2027, the analyst said, although "more fab announcements will be necessary for further upside from current levels."
• Taiwan Semiconductor Manufacturing ranks in the 92nd percentile of the stocks that we track, giving it a Zen Rating of B, which has historically corresponded to an average annual return of 19.88%.
• Our neural network has singled out TSM as a likely outperformer going forward — in terms of Artificial Intelligence, the stock ranks in the top 14%.
• Sentiment is another of the stock’s strengths — here, it ranks in the top 11% of the equities that we track.
• Taiwan Semiconductor Manufacturing shares have rallied by 39.23% since the start of the year — so it’s no wonder that they rank in the 90th percentile when it comes to Momentum.
• With all of that being said, Financials are still the ace up TSM’s sleeve — as the stock ranks in the top 4% in this category. (See all 7 Zen Component Grades here >)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.